Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hematology

Symptoms, Subtypes, and Warning Signs

At a Glance

Familial thrombomodulin anomalies caused by THBD mutations can lead to either abnormal bleeding or small-vessel clots affecting the kidneys and other organs. Recognizing prolonged bleeding, dark urine, swelling, high blood pressure, and sudden neurologic or breathing symptoms helps prompt urgent care.

Because mutations in the THBD gene can act in two opposite ways, your symptoms will generally fall into one of two categories, or “phenotypes.” Knowing which category your specific mutation belongs to—bleeding or clotting—is the most important step in managing your health.

The Bleeding Phenotype: TM-AC

If your mutation causes an overabundance of “floating” thrombomodulin in your blood, you may have Thrombomodulin-Associated Coagulopathy (TM-AC) [1][2]. This condition is primarily a bleeding disorder.

The most common symptoms include:

  • Post-Procedural Bleeding: Excessive or difficult-to-control bleeding after surgery, dental extractions, or childbirth [3][1].
  • Trauma-Related Bleeding: Wounds that bleed for much longer than expected or hematomas (large collections of blood under the skin) after minor impacts [3].
  • Menstrual Changes: Significantly heavy or prolonged menstrual periods.
  • Delayed Clot Breakdown: Because this mutation also affects how the body dissolves clots, laboratory models show a delay in clot breakdown that can contribute to the severity of bleeding after trauma or surgery [4][5].

Importantly, routine blood tests used to check clotting speed (like PT or aPTT) often come back completely normal in people with TM-AC [3]. This can be misleading for doctors who are not familiar with the condition.

The Clotting Phenotype: aHUS and TMA

If your mutation causes a shortage of functional thrombomodulin, you are at risk for Thrombotic Microangiopathy (TMA), often specifically called Atypical Hemolytic Uremic Syndrome (aHUS) [6]. In this version of the condition, tiny clots form inside your small blood vessels, damaging your organs and using up your blood’s “ingredients” (platelets and red blood cells) [7].

Common symptoms of this phenotype include:

  • Kidney Issues: This is often the first sign. You may notice edema (swelling in the legs or around the eyes), decreased urination, or urine that looks dark or “cola-colored” [8][7].
  • Profound Fatigue: Caused by hemolytic anemia, where your body destroys its own red blood cells faster than it can replace them [9].
  • High Blood Pressure: New or suddenly worsening high blood pressure is common during a flare-up [10].
  • Brain and Heart Symptoms: In severe cases, the tiny clots can affect the brain (causing headaches or confusion) or the heart (causing chest pain or shortness of breath) [11][12].

Identifying Emergencies: Red Flags

Not every symptom is an emergency. It is normal for people with the bleeding phenotype to have small, flat bruises from everyday life, and it is normal for anyone to feel tired occasionally. These are not reasons for an emergency visit.

However, because these conditions can change rapidly, you must know the signs of a thrombotic microangiopathy (TMA) crisis or a severe bleeding event.

Call emergency services or go to the nearest emergency room immediately for:

  • Neurologic Changes: Sudden, severe confusion, seizures, loss of vision, or a “thunderclap” headache [11][13].
  • Chest and Lung Signs: New chest pain, a racing heart, or severe shortness of breath, even when resting [14][12].
  • Kidney Failure Signs: A sudden, total stop in urine production or urine that is visibly bloody or very dark [8][15].
  • Uncontrolled Bleeding: Bleeding from a wound or the nose that does not stop after 15 minutes of firm, continuous pressure.
  • Infection while on a C5 inhibitor: Fever, severe headache, neck stiffness, rash, or rapidly worsening illness in a person taking a C5 inhibitor is an extreme emergency [16].
  • Severe Systemic Signs: New, widespread bruising (purpura), jaundice, or sudden severe hypertension [13][17].

In an emergency, tell the medical team you have a “THBD mutation with a risk of Atypical HUS or Thrombomodulin-Associated Coagulopathy.” This helps them prioritize tests like a blood film to look for schistocytes (fragmented red blood cells). While schistocytes are a hallmark of TMA, their absence does not exclude it, and early or evolving TMA requires comprehensive evaluation [13][17].

Common questions in this guide

How can a THBD mutation affect my health?
A THBD mutation can create either a bleeding pattern called thrombomodulin-associated coagulopathy (TM-AC) or a clotting pattern involving small blood vessels, called thrombotic microangiopathy (TMA) and often atypical hemolytic uremic syndrome (aHUS). Your genetic result and clinical evaluation help determine which pattern to monitor.
Can I have TM-AC if my PT and aPTT are normal?
Yes. Routine tests such as PT and aPTT often measure clotting speed normally in people with TM-AC, even when they have excessive bleeding after procedures or injuries. Your bleeding history and specialist evaluation still matter.
What signs could mean a TMA or aHUS flare?
New swelling around the legs or eyes, less urine, dark or cola-colored urine, profound fatigue, or suddenly high blood pressure can signal kidney or blood-cell problems. Headache, confusion, chest pain, or shortness of breath are also concerning and need urgent medical evaluation.
When should I seek emergency care for a THBD-related condition?
Get emergency help for sudden confusion, seizures, vision loss, a thunderclap headache, chest pain, severe shortness of breath, no urine, visibly bloody or very dark urine, or bleeding that does not stop after 15 minutes of firm pressure. Fever with severe headache, neck stiffness, rash, or rapidly worsening illness is also an emergency if you take a C5 inhibitor.
What should I tell my doctor before surgery or dental work?
Tell the medical and dental teams that you have a THBD mutation and whether your known pattern is bleeding or clotting. Ask in advance what precautions, monitoring, and response plan are needed because the risks around procedures can differ by phenotype.
What does a schistocyte test look for?
A blood film lets clinicians look for schistocytes, which are red blood cells broken into fragments and can support a diagnosis of TMA. Their absence does not rule out an early or evolving TMA, so clinicians may need a broader evaluation.

Get notified when new evidence is published on Familial thrombomodulin anomalies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.

    Westbury SK, Whyte CS, Stephens J, et al.

    Journal of thrombosis and haemostasis : JTH 2020; (18(9)):2209-2214 doi:10.1111/jth.14990.

    PMID: 32634856
  2. 2

    A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation.

    Okada M, Tominaga N, Honda G, et al.

    Blood advances 2020; (4(12)):2631-2639 doi:10.1182/bloodadvances.2019001155.

    PMID: 32556284
  3. 3

    Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation.

    Dargaud Y, Scoazec JY, Wielders SJ, et al.

    Blood 2015; (125(9)):1497-501 doi:10.1182/blood-2014-10-604553.

    PMID: 25564403
  4. 4

    Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy.

    Burley K, Whyte CS, Westbury SK, et al.

    Blood 2016; (128(14)):1879-1883 doi:10.1182/blood-2016-05-716092.

    PMID: 27436851
  5. 5

    Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype.

    Morrow GB, Beavis J, Harper S, et al.

    Thrombosis research 2021; (197()):100-108 doi:10.1016/j.thromres.2020.11.002.

    PMID: 33190022
  6. 6

    Atypical Hemolytic Uremic Syndrome: A Brief Review.

    Zhang K, Lu Y, Harley KT, Tran MH

    Hematology reports 2017; (9(2)):7053 doi:10.4081/hr.2017.7053.

    PMID: 28626544
  7. 7

    Atypical Hemolytic Uremic Syndrome Presenting as Acute Heart Failure-A Rare Presentation: Diagnosis Supported by Skin Biopsy.

    Kichloo A, Chugh SS, Gupta S, et al.

    Journal of investigative medicine high impact case reports 2019; (7()):2324709619842905 doi:10.1177/2324709619842905.

    PMID: 31010328
  8. 8

    Atypical hemolytic uremic syndrome in kidney transplantation.

    Ponticelli C, Moroni G

    Journal of nephrology 2026; (39(7)):1334-1341 doi:10.1093/joneph/aajag096.

    PMID: 42742155
  9. 9

    A Rare Case of Atypical Hemolytic Uremic Syndrome Presenting as Chronic Interstitial Nephritis.

    Muralidharan S, Mathew GG, Alwan A, Jayaprakash V

    Cureus 2024; (16(7)):e65274 doi:10.7759/cureus.65274.

    PMID: 39184759
  10. 10

    Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome.

    El Karoui K, Boudhabhay I, Petitprez F, et al.

    Haematologica 2019; (104(12)):2501-2511 doi:10.3324/haematol.2019.216903.

    PMID: 30890598
  11. 11

    Extra-Renal manifestations of atypical hemolytic uremic syndrome in children.

    Fidan K, Göknar N, Gülhan B, et al.

    Pediatric nephrology (Berlin, Germany) 2018; (33(8)):1395-1403 doi:10.1007/s00467-018-3933-3.

    PMID: 29610995
  12. 12

    Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy.

    Campbell CM, Cassol C, Cataland SR, Kahwash R

    European heart journal. Case reports 2020; (4(2)):1-6 doi:10.1093/ehjcr/ytaa050.

    PMID: 32352052
  13. 13

    Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.

    Fox LC, Cohney SJ, Kausman JY, et al.

    Nephrology (Carlton, Vic.) 2018; (23(6)):507-517 doi:10.1111/nep.13234.

    PMID: 29419916
  14. 14

    A case report of atypical hemolytic uremic syndrome with a CFH mutation complicated by recurrent posterior reversible encephalopathy syndrome.

    Maruyama R, Takeuchi D, Momose M, et al.

    Medicine 2026; (105(27)):e49593 doi:10.1097/MD.0000000000049593.

    PMID: 42410819
  15. 15

    Atypical Hemolytic Uremic Syndrome Triggered by COVID-19 Infection in a Pediatric Patient With CD46 Mutation.

    Lorestani P, Maleki Dana P, Tohidi MR

    Clinical case reports 2025; (13(3)):e70308 doi:10.1002/ccr3.70308.

    PMID: 40093928
  16. 16

    TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells.

    Sartain SE, Turner NA, Moake JL

    Journal of immunology (Baltimore, Md. : 1950) 2016; (196(2)):832-45 doi:10.4049/jimmunol.1500960.

    PMID: 26673143
  17. 17

    Thrombotic Microangiopathies.

    Hanna R, Gibney R, Boysen-Osborn M

    Emergency medicine clinics of North America 2025; (43(3)):407-420 doi:10.1016/j.emc.2025.03.008.

    PMID: 40610058

This page is for informational purposes only and does not constitute medical advice about a THBD mutation. Contact your healthcare team for individualized monitoring, and seek emergency care for severe bleeding or sudden neurologic, chest, breathing, or kidney symptoms.